Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Status unconfirmed · Phase 2
Conditions studied: Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer
In brief
This study is being conducted to compare the efficacy and safety of tesetaxel administered once every 3 weeks in a 21-day cycle, tesetaxel administered once weekly for 3 consecutive weeks in a 28-day cycle, and capecitabine administered twice daily for 14 consecutive days in a 21-day cycle.
Key facts
- Study ID
- NCT01609127
- Run by
- Genta Incorporated
- People needed
- 213
- Starts
- 2012-05-01
- Expected to finish
- 2014-07-01
- Last updated by the study team
- 2012-06-01
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- The West Clinic — Memphis, Tennessee, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.